Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- CheckyesterdayChange DetectedThe page shows a new status: Active, not recruiting, and the revision version was updated to v3.4.2. Additionally, a contact phone number and the Recruiting label were removed.SummaryDifference0.3%
- Check9 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1, indicating a minor maintenance update rather than content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check16 days agoChange DetectedNo significant changes detected between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.0%
- Check23 days agoChange DetectedThe Study Record Dates section now shows 'Last Update Posted' instead of 'Last Update Posted (Estimated)'.SummaryDifference0.0%
- Check30 days agoChange DetectedRevision metadata updated from v3.3.3 to v3.3.4; no substantive study content (eligibility criteria, endpoints, locations, or results) appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check52 days agoChange DetectedUpdated the study's Locations section to add new site locations across the United States and internationally, while removing several previously listed sites. This changes where participants can enroll and access the trial.SummaryDifference2%
Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.